Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Positron CEO sees bright prospects for the company next year

Patrick G. Rooney, the Chairman of the Board of Positron Corporation,a molecular imaging company focused on Nuclear Cardiology, has confirmed in an interview with BioMedReports that while his company will be profitable this year, he sees it becoming much more profitable next year and so on -- year over year going forward.

Interestingly, his estimates do not include some of the resources and capabilities that will be brought to the table for POSC by some of the partnerships that are about to be announced.

BioMedReports learned yesterday that while POSC 's position as the leading Cardio PET imaging manufacturer makes the company attractive to investors, its revolutionary Pharm-Assist automated radiopharmaceutical distribution device is what has attracted the attention of not only one multi-billion dollar NYSE company which has already inked a yet-to-be announced deal with Positron, but other publicly traded, big cap companies as well.

"Our machine is not only a very attractive option for patients and doctors, but also to many of the current companies and drug manufacturers who deal in the cardiac and oncology imaging space," explains Rooney in a new exclusive interview with BioMedReports. "Instead of taking on the expense of opening up a brick and mortar location for $3+ million and being worried about the expensive overhead and personnel costs of selling radiopharmaceuticals, we can install this inexpensive, automated device that is compliant with all the U.S. rules and regulations for safety and exposure issues. It works well in emergency rooms, in cardiology offices, etc. There are many benefits to it, including the fact that it saves a great deal of money, gas, and time. In addition, if you're trying to get a dose and you're the 10th person in line ordering, you may not get the dose. With our system, you're guaranteed to get a dose."

With their new machine, POSC brings both imaging and dose dispensing of radiopharmaceuticals right into the doctor's office.

"These technologies have brought us a wave of new interest for partnerships, strategic alliances and, frankly, we're having to start staffing and hiring much faster than ever before," says Rooney. "We're a company that has been waiting for the evolution to come and now we find that it's coming on stronger than we thought."

"Although it has taken some time, development and really honing in all of our components, we are there now. We will be profitable this year, much more profitable next year and so on -- year over year going forward; and that doesn't include some of the resources and capabilities that will be brought to the table by some of the partnerships that are about to be announced. Once you add those relationships, the revenue and profit numbers increase significantly. It's very significant."

The complete special report and interview is available at BioMedReports.Com

http://biomedreports.com/articles/most-popular/38340-positron-ceo-believes-impact-of-new-technology-and-partnerships-will-make-company-significantly-more-profitable-than-ever.html

Biotech investors interested in accessing the news portal's database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

Source: BioMedReports